Filing Flows › Fennec Pharmaceuticals (FENC) › Q1 2025
Fennec Pharmaceuticals (FENC) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 14, 2025
Fennec Pharmaceuticals (FENC) reported revenue of $8.8M for the first quarter 2025 (Q1 2025), -66% from a year earlier and +10% from the quarter before. Operating margin was -9.2%, net loss $1.2M (13.3% of revenue).
Fennec Pharmaceuticals, Q1 2025: revenue $8.8M (-66% year over year), operating margin -9.2%, net loss $1.2M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.8M | +10% | -66% |
| Operating profit | −$808K | — | — |
| Net earnings | −$1.2M | — | — |
| Operating cash flow | −$4.3M | — | — |
What changed
Revenue was $8.8M in Q1 2025, down 66% year over year and up 10% from the previous quarter.
Operating costs exceeded revenue by $808K, an operating margin of -9.2%. Total costs fell 18% while revenue fell 66%. The fastest-growing cost line was Research & development (+3033%). The quarter ended with a net loss of $1.2M, narrower than the previous quarter's $2.0M loss.
Operating cash flow was −$4.3M. Non-cash charges added back $798K of share-based compensation. Working capital and other items used $4.0M.
Questions
What was Fennec Pharmaceuticals' revenue in the first quarter 2025?
Fennec Pharmaceuticals (FENC) reported revenue of $8.8M for the first quarter 2025 (Q1 2025), -66% from a year earlier and +10% from the quarter before.
Was Fennec Pharmaceuticals profitable in the first quarter 2025?
Operating loss was $808K (-9.2% of revenue) and net loss $1.2M.